CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The FAIR project aims to enhance antibiotic treatment for pneumonia by using an immunomodulatory agent delivered via nebulization. This approach seeks to combat antibiotic resistance and improve patient outcomes by strengthening the immune response alongside traditional therapies.
Bacterial pneumonia is a leading cause of morbidity and mortality worldwide.
Antibiotics constitute the standard of care but are faced with the emergence of antimicrobial resistance (AMR) and the curative failure.
The FAIR consortium aims at assessing an adjunct to antibiotic therapy as an emerging concept of overcome AMR in pneumonia.
The project leverages (i) a unique immunomodulatory flagellin that enhances airway epithelial innate immune defences and increases the therapeutic outcome relativ…
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Tours
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, PARIS
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
